 Home > Biochemistry News > Biotechnology News > FDA approves the first non-stimulant ADHD therapy in ten years, which is expected to benefit nearly 1 in 10 children

FDA approves the first non-stimulant ADHD therapy in ten years, which is expected to benefit nearly 1 in 10 children

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

coronavirus treatment

denture stomatitis treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, Supernus Pharmaceuticals announced that the US FDA has approved the company's Qelbree (viloxazine sustained-release capsules) to be marketed for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients aged 6-17.

ADHD, commonly known as hyperactivity, is a chronic brain disease characterized by inability to concentrate, hyperactivity, and impulsivity.

Qelbree developed by Supernus is a norepinephrine reuptake inhibitor with specific serotonin regulatory activity.

Qelbree's approval is supported by 4 phase 3 clinical trials involving more than 1,000 pediatric patients aged 6-17 years.

"Based on the efficacy shown in the clinical development project, we believe that Qelbree provides a unique alternative treatment for ADHD.

Reference materials:

[1] Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.